Leading Israel-based drugs group Teva Pharmaceutical Industries is the third major to set up operations in Japan, aiming to take advantage of the still small but growing copy-cat drugs market there.
In March, Teva, which since its acquisition of US firm IVAX is the world's largest generics group (Marketletters passim), applied for approval to sell its products in Japan, with an eye to marketing drugs already available in the USA and Europe, reports the Nikkei Weekly. The firm plans to gradually expand its offerings, rolling out two injection products in 2007 and is set to hire sales and technical personnel for its Japanese subsidiary, according to the newspaper.
In Japan, generic drugs accounted for around 16% of prescription medicines sales by volume in fiscal 2003. The world's second-largest generics firm, Sandoz (a unit of Swiss drug major Novartis), and Germany-based Merck KGaA, which also has a substantial me-too drugs business, are also established in Japan, says the Nikkei.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze